Group 1 - The recombinant protein concept sector declined by 0.82%, ranking among the top declines in concept sectors, with notable declines in companies such as Kexing Pharmaceutical, Jieya Co., and Yipinhong [1] - Among the 14 stocks that rose, Furuida, Borui Pharmaceutical, and Saiseng Pharmaceutical had the highest increases of 10.06%, 3.54%, and 2.90% respectively [1] - The sector experienced a net outflow of 232 million yuan from main funds, with 35 stocks seeing net outflows, and five stocks experiencing outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock was Saiseng Pharmaceutical, with a net outflow of 65.48 million yuan, followed by Xilong Science, Zhongyuan Qihe, and Borui Pharmaceutical with net outflows of 61.32 million yuan, 53.12 million yuan, and 51.87 million yuan respectively [2][3] - The stocks with the highest net inflows included Furuida, Maiwei Bio, and Ruizhi Pharmaceutical, with net inflows of 189 million yuan, 39.29 million yuan, and 18.25 million yuan respectively [2] - The trading volume and price changes of various stocks in the recombinant protein sector indicate significant market activity, with Saiseng Pharmaceutical showing a trading rate of 35.58% despite the outflow [3]

Core Viewpoint - The legal opinion letter issued by Guangdong Xinda Law Firm confirms the compliance of Beijing Kain Technology Co., Ltd.'s differentiated equity distribution plan for the 2024 profit distribution, ensuring it aligns with relevant laws and regulations [1][7]. Group 1: Differentiated Equity Distribution Plan - The company plans to distribute a cash dividend of 50,230,618.50 yuan (including tax) to all shareholders, which is 35.28% of the net profit attributable to shareholders in the consolidated financial statements [4][5]. - The total number of shares eligible for the distribution is 167,435,395, after excluding 3,509,027 shares held in the company's repurchase account [4][6]. - The company will not conduct capital reserve transfers or issue bonus shares in this distribution [4]. Group 2: Reasons for Differentiated Equity Distribution - The company has approved a share repurchase plan using its own funds, with a total amount between 60 million yuan and 120 million yuan, and a repurchase price not exceeding 26 yuan per share [5][6]. - The repurchased shares will be used for employee stock ownership plans and must be transferred within three years after the announcement of the repurchase results [5][6]. Group 3: Compliance and Legal Basis - The differentiated equity distribution complies with the Company Law, Securities Law, and relevant self-regulatory guidelines, ensuring that shares held in the repurchase account do not participate in profit distribution [6][7]. - The legal opinion confirms that the distribution does not harm the interests of the company or its shareholders [8].

Core Viewpoint - The company, Beijing Kain Technology Co., Ltd., has announced a differentiated cash dividend distribution plan for its shareholders, which was approved at the 2024 annual general meeting on May 20, 2025 [1][2]. Dividend Distribution Plan - The company plans to distribute a cash dividend of 0.30 yuan per share (including tax) to all shareholders [1][3]. - The total share capital as of December 31, 2024, is 170,944,422 shares, with 3,509,027 shares held in the company's repurchase account, resulting in a distribution base of 167,435,395 shares [2][3]. - The cash dividend distribution will not involve capital reserve transfers or stock dividends, meaning the number of circulating shares will remain unchanged [3]. Relevant Dates - Key dates for the dividend distribution include the record date, ex-dividend date, and cash dividend payment date, which are specified in the announcement [1][4]. Tax Implications - For individual shareholders holding shares for more than one year, the cash dividend income is exempt from personal income tax, resulting in a net cash dividend of 0.30 yuan per share [4][5]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but tax will be calculated and deducted upon the transfer of shares [4][5]. - Qualified Foreign Institutional Investors (QFII) will have a 10% corporate income tax withheld on the dividends, leading to a net cash dividend of 0.27 yuan per share [6][7]. Implementation of Distribution - Shares held in the company's repurchase account will not participate in the profit distribution [4]. - Cash dividends for certain institutional shareholders will be distributed directly by the company, while others will be managed through the China Securities Depository and Clearing Corporation [4][6].

关于 北京凯因科技股份有限公司 差异化权益分派事项的法律意见书 中国 深圳 福田区益田路6001号太平金融大厦11、12层 邮政编码：518038 11-12/F, Taiping Finance Tower, Yitian Road No.6001, Futian District, Shenzhen 518038 电话(Tel)：(0755)88265288 传真(Fax)：(0755)88265537 电子邮件（E-mail）：info@sundiallawfirm.com 网站（Website）：sundiallawfirm.com 致：北京凯因科技股份有限公司 广东信达律师事务所（以下简称"信达"）接受贵公司的委托，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司股份回购规则》《上 海证券交易所交易规则》《上海证券交易所上市公司自律监管指引第 7 号——回 购股份》等有关法律、法规及规范性文件的规定，就贵公司 2024 年度利润分配 涉及的差异化权益分派特殊除权除息（以下简称"本次差异化权益分派"）的合 规性等相关事项出具《广东信达律师事务所关于北京凯因科技股份有限公司差异 化权益分 ...

证券代码：688687 证券简称：凯因科技 公告编号：2025-021 北京凯因科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/10 | 2025/6/11 | 2025/6/11 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 20 日的2024年年度股东大会审议通过。 二、 分配方案 是否涉及差异化分红送转：是 每股分配比例 每股现金红利0.30元（含税） 相关日期 1. 发放年度：2024年年度 2. 分派对象： 3. 差异化分红送转方案： （1）差异化分红方案 根据公司 2024 年年度股东大会审议通过的《关于公司 2024 年度利润分配方 案的议案》，公司拟向全体股东每 10 股派发现金红利 3.00 元（含税）。截至 2024 年 12 月 31 日，公司总股本 170,944,422 股，扣除 ...

Market Overview - The three major stock indices collectively rose today, with nearly 4,000 stocks increasing in value. Key sectors showing strong performance include brokerage firms and diversified financials, as well as consumer goods and innovative pharmaceuticals [1] - The trading volume in the Shanghai and Shenzhen markets reached 1.15 trillion, indicating no significant increase in trading activity [1] Sector Performance - The beer and soft drink sectors performed well, driven by seasonal demand due to high summer temperatures. Stocks such as 嘉美包装 (Jia Mei Packaging), 乐惠国际 (Le Hui International), and 永顺泰 (Yong Shun Tai) hit their daily limit [1] - Recent trends show a concentration of capital in specific sectors, with significant interest in metals, non-metals, and mining due to rising global risk aversion and domestic resource policies. Key stocks include 紫金矿业 (Zijin Mining) and 赤峰黄金 (Chifeng Jilong Gold Mining) [5] - The electric equipment sector, particularly in renewable energy and nuclear power, is benefiting from technological breakthroughs and policy support. Notable stocks include 宁德时代 (CATL) and 中超控股 (Zhongchao Holdings) [5] Investment Trends - There is a noticeable trend of large funds "hugging" certain stocks, leading to repeated speculation on a few hot topics. This has resulted in significant short-term profit opportunities, although the sustainability of this trend is questionable [6] - High-profile stocks have seen substantial price increases without strong fundamental support, indicating that the market is driven by speculative trading rather than underlying business improvements [5][6] - Recent data shows that some high-performing stocks have experienced insider selling, with executives from 凯因科技 (Kain Technology) and 均瑶健康 (Jun Yao Health) reducing their holdings significantly [7][8]

Core Viewpoint - Kain Technology (688687.SH) has completed a share reduction plan, with shareholders reducing their holdings by 5,127,999 shares, representing 3.00% of the company's total share capital, resulting in approximately 126 million yuan in cash proceeds [1][2]. Group 1: Share Reduction Details - The shareholders involved in the reduction are Beijing Fushanwan Investment Management Center, Beijing Funingwan Investment Management Center, Beijing Zhuoshangshi Investment Management Center, and Beijing Zhuoshangwan Enterprise Management Center [1]. - The share reduction took place from May 16 to May 29, 2023, through block trades and centralized bidding [1]. - The total number of shares reduced was 5,127,999, which is exactly 3.00% of the company's total share capital [1]. Group 2: Company Background and Financials - Kain Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 8, 2021, with an initial offering price of 18.98 yuan per share [2]. - On its first trading day, the stock reached a peak price of 70.00 yuan, marking the highest point since its listing [2]. - The company raised a total of 806 million yuan from its initial public offering, with a net amount of 726 million yuan after deducting issuance costs [2]. - The intended fundraising amount was 1.092 billion yuan, allocated for new drug research and development, marketing network expansion, and working capital [2]. Group 3: Recent Corporate Decisions - On April 28, 2025, Kain Technology's board of directors and supervisory board approved the termination of a simplified procedure for issuing shares to specific targets [3].

证券代码：688687 证券简称：凯因科技 公告编号：2025-020 重要内容提示： 股东持股的基本情况 本次减持计划实施前，北京凯因科技股份有限公司（以下简称"公司"）股 东：北京富山湾投资管理中心（有限合伙）（以下简称"富山湾"）直接持有公司 股份 3,156,600 股，占公司总股本的 1.85%；北京富宁湾投资管理中心（有限合 伙）（以下简称"富宁湾"）直接持有公司股份 3,113,100 股，占公司总股本的 1.82%；北京卓尚石投资管理中心（有限合伙）（以下简称"卓尚石"）直接持有 公司股份 1,673,300 股，占公司总股本的 0.98%；北京卓尚湾企业管理中心（有 限合伙）（以下简称"卓尚湾"）直接持有公司股份 1,043,922 股，占公司总股本 的 0.61%。富山湾、富宁湾、卓尚石、卓尚湾均属于公司实际控制人周德胜能够 控制的企业，上述股东合计持有公司股份 8,986,922 股，占公司总股本的 5.26%。 上述股份均为公司首次公开发行股票并上市前所取得的股份，且已于 2024 年 2 月 8 日全部解除限售并上市流通。 减持计划的实施结果情况 2025 年 4 月 22 日,公司 ...

金十数据5月30日讯，凯因科技公告，股东富山湾、富宁湾、卓尚石及卓尚湾因其持有人自身资金需 求，通过大宗交易及集中竞价交易的方式累计减持公司股份512.8万股，占公司总股本的3.00%。本次减 持计划已实施完毕。 凯因科技：富山湾、富宁湾、卓尚石及卓尚湾合计减持512.8万股 ...

Core Viewpoint - The company, Kaiyin Technology, is actively advancing its drug development projects and has reported positive financial performance in Q1 2025, indicating growth potential in the biopharmaceutical sector focused on viral and immune diseases [6][8]. Group 1: Drug Development Progress - The company has received acceptance for its new drug application for chronic hepatitis B treatment by the National Medical Products Administration in September 2024, with further updates to be provided by regulatory announcements [2]. - In 2025, the company plans to accelerate the clinical progress of several projects, including KW-051 for shingles, KW-045 for herpetic pharyngitis, and KW-053 for genital warts, while also focusing on the Phase I clinical study of a new drug KW-040 [3]. - The company is concentrating on innovative drug development for functional cure of hepatitis B, with ongoing clinical trials for KW-001 and KW-027, and has submitted a clinical trial application for KW-040 [6]. Group 2: Market Position and Competition - The domestic hepatitis C market presents significant growth opportunities, with the company’s product, Kailiwei, expected to leverage its competitive advantages in product strength and promotional strategies to achieve breakthroughs [4]. - The company is enhancing the brand influence of its product Jinshuxi, which has been included in the Jiangxi centralized procurement, aiming for increased market share through strategic channel optimization and cancer screening initiatives [5]. Group 3: Financial Performance - In Q1 2025, the company reported a main revenue of 232 million yuan, an increase of 8.9% year-on-year, and a net profit of approximately 25.67 million yuan, reflecting a 15.92% year-on-year growth [6]. - The company’s gross profit margin stands at 82.95%, with a debt ratio of 24.29%, indicating a strong financial position [6]. - Recent institutional ratings show 5 buy ratings and 2 hold ratings, with an average target price of 44.97 yuan over the past 90 days [6][8].